Association of Black Cardiologist
Reduce The Gap
Our Goal is to Reduce the Cardiovascular Disease Disparity Gap by 20% by 2020
Read More

Xarelto® Announcement.

November 2011

Dear The Association of Black Cardiologists,

The FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS), which consists of a Medication Guide and a Communication Plan, is necessary to ensure that the benefits of XARELTO® (rivaroxaban) outweigh the potential risks to patients with nonvalvular atrial fibrillation, including:

Respectfully,

Chris Herbine
National Advocacy Director
Janssen Pharmaceuticals, Inc.©